These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23504381)

  • 1. Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome.
    Martinez-Gamboa L; Lesemann K; Kuckelkorn U; Scheffler S; Ghannam K; Hahne M; Gaber-Elsner T; Egerer K; Naumann L; Buttgereit F; Dörner T; Kloetzel PM; Burmester GR; Faustman DL; Feist E
    J Rheumatol; 2013 May; 40(5):663-73. PubMed ID: 23504381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders.
    Krause S; Kuckelkorn U; Dörner T; Burmester GR; Feist E; Kloetzel PM
    Ann Rheum Dis; 2006 Aug; 65(8):1021-7. PubMed ID: 16414974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i).
    Scheffler S; Kuckelkorn U; Egerer K; Dörner T; Reiter K; Soza A; Burmester GR; Feist E
    Rheumatology (Oxford); 2008 May; 47(5):622-6. PubMed ID: 18375405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
    Busse A; Kraus M; Na IK; Rietz A; Scheibenbogen C; Driessen C; Blau IW; Thiel E; Keilholz U
    Cancer; 2008 Feb; 112(3):659-70. PubMed ID: 18181098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
    Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
    Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of proteasomal immunosubunit beta1i is dysregulated in inflammatory infiltrates of minor salivary glands in Sjogren's syndrome.
    Morawietz L; Martinez-Gamboa L; Scheffler S; Hausdorf G; Dankof A; Kuckelkorn U; Doerner T; Egerer K; Burmester GR; Faustman DL; Feist E
    J Rheumatol; 2009 Dec; 36(12):2694-703. PubMed ID: 19833746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndrome.
    Egerer T; Martinez-Gamboa L; Dankof A; Stuhlmüller B; Dörner T; Krenn V; Egerer K; Rudolph PE; Burmester GR; Feist E
    Arthritis Rheum; 2006 May; 54(5):1501-8. PubMed ID: 16646031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.
    Sellam J; Miceli-Richard C; Gottenberg JE; Ittah M; Lavie F; Lacabaratz C; Gestermann N; Proust A; Lambotte O; Mariette X
    Ann Rheum Dis; 2007 Jun; 66(6):790-7. PubMed ID: 17185325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of interferon regulatory factor 1, 3, and 7 in primary Sjögren syndrome.
    Zheng L; Yu C; Zhang Z; Yang C; Cai X
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 May; 107(5):661-8. PubMed ID: 19426920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model.
    Yao X; Liu J; McCabe JT
    J Neurochem; 2008 Jan; 104(2):353-63. PubMed ID: 17944870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation profile of the promoter region of IRF5 in primary Sjögren's syndrome.
    Gestermann N; Koutero M; Belkhir R; Tost J; Mariette X; Miceli-Richard C
    Eur Cytokine Netw; 2012; 23(4):166-72. PubMed ID: 23302156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement factor C3a alters proteasome function in human RPE cells and in an animal model of age-related RPE degeneration.
    Ramos de Carvalho JE; Klaassen I; Vogels IM; Schipper-Krom S; van Noorden CJ; Reits E; Gorgels TG; Bergen AA; Schlingemann RO
    Invest Ophthalmol Vis Sci; 2013 Oct; 54(10):6489-501. PubMed ID: 23982842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome.
    Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X
    Scand J Immunol; 2008 Feb; 67(2):185-92. PubMed ID: 18201372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
    Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
    Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
    J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
    Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J
    Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain-derived neurotrophic factor and nerve growth factor correlate with T-cell activation in primary Sjogren's syndrome.
    Fauchais AL; Boumediene A; Lalloue F; Gondran G; Loustaud-Ratti V; Vidal E; Jauberteau MO
    Scand J Rheumatol; 2009; 38(1):50-7. PubMed ID: 18830907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.